Calidi Biotherapeutics, Inc.
CLDI
$1.59
$0.053.25%
AMEX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -24.10% | -21.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.25% | -11.53% | |||
| Operating Income | 6.25% | 11.53% | |||
| Income Before Tax | -1.06% | 21.47% | |||
| Income Tax Expenses | 300.00% | -120.00% | |||
| Earnings from Continuing Operations | -1.21% | 21.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -90.63% | |||
| Net Income | -1.28% | 21.23% | |||
| EBIT | 6.25% | 11.53% | |||
| EBITDA | -19.66% | 36.36% | |||
| EPS Basic | 24.76% | 74.18% | |||
| Normalized Basic EPS | 34.06% | 42.13% | |||
| EPS Diluted | 24.76% | 74.18% | |||
| Normalized Diluted EPS | 34.06% | 42.13% | |||
| Average Basic Shares Outstanding | 44.75% | 45.13% | |||
| Average Diluted Shares Outstanding | 44.75% | 45.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||